Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
SMI 12’316 0.0%  SPI 17’066 0.0%  Dow 45’515 0.3%  DAX 23’839 0.1%  Euro 0.9327 0.0%  EStoxx50 5’386 0.4%  Gold 3’644 0.2%  Bitcoin 89’643 0.9%  Dollar 0.7937 0.0%  Öl 66.7 0.7% 
Beliebte Suchen
SMI Öl Schweizer Franken - Euro Bitcoin Goldpreis
Top News
So bewegen sich die Kurse von Bitcoin, Ripple, Bitcoin Cash und Ethereum am Dienstagvormittag
BMW-Aktie stabil: BMW bleibt bei langfristigem Margenkorridor - Strategie bekräftigt
Fresenius-Aktie freundlich: Fresenius stärkt Finanzierung mit Milliarden-Anleihen
Meyer Burger-Aktie soll dekotiert werden - Handel bleibt weiter ausgesetzt
Kurssprung oder Kursverfall? So weit klaffen die Analystenmeinungen für die Allianz-Aktie auseinander
Suche...
200.- Saxo-Deal

Springer Nature Aktie 41578404 / DE000SPG1003

Kurse + Charts + Realtime News + Analysen Fundamental Unternehmen zugeh. Wertpapiere Aktion
Kurs + Chart Chart (gross) News + Adhoc Bilanz/GuV Termine Strukturierte Produkte Portfolio
Times + Sales Chartvergleich Analysen Schätzungen Profil Trading-Depot Watchlist
Börsenplätze Realtime Push Kursziele Dividende/GV
Orderbuch Analysen
Historisch
Kurse + Charts + Realtime

Kurs + Chart

Chart (gross)

Times + Sales

Chartvergleich

Börsenplätze

Realtime Push

Orderbuch

Historisch

News + Analysen

News + Adhoc

Analysen

Kursziele

Fundamental

Bilanz/GuV

Schätzungen

Dividende/GV

Analysen

Unternehmen

Termine

Profil

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

13.08.2025 07:00:03

EQS-News: Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

Springer Nature
23.60 EUR 0.85%
Kaufen Verkaufen

EQS-News: Springer Nature AG & Co. KGaA / Key word(s): Half Year Results
Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

13.08.2025 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

 

PRESS RELEASE
 

Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance 
  • Strong performance with 6% underlying1 revenue growth and 10% underlying1 adjusted operating profit growth (AOP)
  • Research is key growth driver (7%); Journals outgrowing the market
  • Free cash flow up 51% to €204 million; leverage ratio reduced to 1.9x
  • Continued progress on AI as a strategic priority
  • Full-year 2025 guidance raised for both revenue and AOP

Berlin, 13 August 2025

Springer Nature, a leading global science publisher, today announced strong results for the first half of 2025. On an underlying1 basis, group revenue rose by 6% and adjusted operating profit (AOP) by 10%. First-half revenue increased to €926 million and AOP to €241 million, supported by a favourable revenue mix. Growth was driven by the Research segment. Nearly all 2025 contract renewals have been completed and continued high submission volumes to the Journals portfolio have driven further above-market publication growth. Reflecting this strong performance, the company has raised its full-year guidance for both revenue and AOP.

Frank Vrancken Peeters, CEO of Springer Nature, said: “In the year Springer Nature celebrates its 10th anniversary we’re publishing more high-quality science than ever and continuing to enhance our services for authors and researchers — something we’re truly proud of. This strong first half performance, which outpaces the market, reflects our leadership in open access and the impact of our long-term technology investments.”

Research, the company’s largest segment, reported revenue of €731 million. The segment contributed most significantly to operating performance, with underlying1 revenue growth of 7%. This was driven by the Journals portfolio and the continued momentum in open access (OA) globally. The number of published articles rose by approximately 10% across the whole portfolio and around 25% in Full Open Access (FOA) journals.

By mid-year, Springer Nature had completed nearly all its 2025 contract renewals and signed 17 transformative agreements to further accelerate the shift to OA. The company also launched 24 new journals and is preparing two additional Nature titles for early 2026. Digital book formats continued to grow, offsetting declines in print, with digital now representing about 70% of book sales.

The company continued to invest in a range of initiatives to support growth and ensure research integrity. It also maintained a focus on developing AI tools to transform the publication process, provide more value to communities and create new revenue streams. Among these tools is the new AI-powered Nature Research Assistant, which recently entered public beta testing. It is designed to make some of the most time-consuming parts of the research process, including reading and writing, quicker and easier.

In Health, revenue was €90 million. The underlying1 revenue growth of 4% was supported by strong performance in scientific affairs services following a refocus of the international pharma division and solid performance in the Dutch events and books business. Education revenue amounted to €105 million, with underlying1 revenue growth of 3% driven by strong performance in Curriculum, particularly in Latin America.  

Free cash flow rose by €69 million to €204 million in the first half of the year, largely due to the improved operating performance and lower interest payments. The company further reduced financial leverage to 1.9x net debt to adjusted EBITDA, versus its target range of 1.5x to 2.0x. The adjusted net result in the first half of 2025 was €166 million, up from €113 million in the same period last year. 

As a result of its strong performance, Springer Nature has raised its guidance for 2025. The company now expects revenue to be in the range of €1,930 million to €1,960 million and AOP between €540 million to €560 million. This guidance is based on the underlying performance, excluding effects from year-on-year changes in foreign currencies and portfolio.

Alexandra Dambeck, the company’s CFO, said: “Our updated guidance reflects the strong momentum we have seen in the first half of the year and the continued strength of our portfolio. We are also making clear progress in strengthening our balance sheet, supported by robust free cash flow, which gives us the flexibility to pursue sustainable growth and deliver value to our stakeholders.”
 
Springer Nature financial KPI H1 2025
 
Performance indicators at a glance
in € million H1 2025 H1 2024 Change Underlying
change
Revenue 925.9 883.1 4.8% 6.2%
Adjusted operating profit 240.6 225.3 6.8% 9.8%
Free cash flow 203.8 134.9 68.9  
Financial leveragea,b 1.9x 2.3x    
a    Financial leverage of 2.3x refers to 31 December 2024.
b    Financial leverage is defined as net financial debt divided by the past 12 months’ adjusted EBITDA. Adjusted EBITDA is defined as EBITDA before capital gains/losses from the acquisition/disposal of businesses/investments and exceptional items. Net financial debt is defined as interest-bearing loans and borrowings including lease liabilities minus cash and cash equivalents.

 
Notes relating to forward-looking statements
This document contains statements about the future business development and strategic direction of the company. The forward-looking statements are based on management’s current expectations and assumptions. They are subject to certain risks and fluctuations as described in other publications, in particular in the risk and opportunities section of the combined management report. If these expectations and assumptions do not apply or if unforeseen risks arise, the actual course of business may differ significantly from the expected developments. We therefore assume no liability for the accuracy of these forecasts.
 

About Springer Nature
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are a pioneer in open research. Through our leading brands, trusted for more than 180 years, we provide technology-enabled products, platforms and services that help researchers to uncover new ideas and share their discoveries, health professionals to stay at the forefront of medical science, and educators to advance learning. We are proud to be part of progress, working together with the communities we serve to share knowledge and bring greater understanding to the world. For more information, please visit about.springernature.com and @SpringerNature.

 
 
Contact

Cornelius Rahn | Springer Nature | Communications and Corporate Affairs
tel +49 151 1563 7515 | cornelius.rahn@springernature.com

 

1Underlying change excludes effects from year-on-year changes in foreign currencies and portfolio.

 


13.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Springer Nature AG & Co. KGaA
Heidelberger Platz 3
14197 Berlin
Germany
Phone: +49 (0)30 - 82787 - 0
E-mail: ir@springernature.com
Internet: www.springernature.com
ISIN: DE000SPG1003
WKN: SPG100
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Vienna MTF)
EQS News ID: 2183086

 
End of News EQS News Service

2183086  13.08.2025 CET/CEST

Nachrichten zu Springer Nature

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
mehr Nachrichten

Analysen zu Springer Nature

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
15.08.25 Springer Nature Buy Goldman Sachs Group Inc.
13.08.25 Springer Nature Overweight JP Morgan Chase & Co.
31.07.25 Springer Nature Buy Deutsche Bank AG
04.07.25 Springer Nature Overweight Barclays Capital
01.07.25 Springer Nature Overweight JP Morgan Chase & Co.
mehr Analysen
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Krypto-Ausblick 2025: Bitcoin, Ethereum & Altcoins – Wohin geht die Reise? | BX Swiss TV

Bitcoin 2025: Steigt der Kurs noch auf 140.000 USD? Prognose & Einblicke mit Bernhard Wenger

Moderator David Kunz spricht mit Bernhard Wenger über die Zukunft von Bitcoin und Kryptowährungen. Im Gespräch geht es um Kursprognosen, die wichtigsten Einflussfaktoren auf den Kryptomarkt sowie spannende Anlageprodukte wie Indizes, Baskets und tokenisierte Assets.

Themen im Video:
🔹 Bitcoin – Kursprognose bis Jahresende: 140.000 USD möglich?
🔹 Was treiben Zinsen, Inflation & Geopolitik mit dem Kryptomarkt?
🔹 Auswirkungen der Bitcoin-ETFs in den USA
🔹 Institutionelle Investoren: Kommt jetzt der grosse Einstieg?
🔹 Welche Altcoins haben Potenzial? (Ethereum, Solana, Sui & mehr)
🔹 Baskets & Indizes: Diversifikation für Krypto-Investoren
🔹 Kombinationen wie Bitcoin & Gold im Portfolio
🔹 Tokenisierung: Die nächste grosse Welle in der Finanzwelt
🔹 Langfristige Prognosen: Was bedeutet ein einziger Bitcoin in 2030?

Krypto-Ausblick 2025: Bitcoin, Ethereum & Altcoins – Wohin geht die Reise? | BX Swiss TV

Inside Trading & Investment

09:15 Raiffeisen: Produkte im Fokus - 7.00% p.a. Multi Barrier Reverse Convertible auf Swiss Life, Swisscom, UBS
09:13 Schwergewichte belasten
09:09 Marktüberblick: Deutsche Telekom unter Druck
09:00 Logo WHS Eine Aktie, eine Option - Börseneinkommen leicht gemacht - Kostenlose Webinarreihe heute um 10:00 Uhr
06:30 Krypto-Ausblick 2025: Bitcoin, Ethereum & Altcoins – Wohin geht die Reise? | BX Swiss TV
06:14 UBS Logo UBS KeyInvest: SMI – Schwacher Wochenauftakt
04.09.25 Julius Bär: 10.75% p.a. JB Callable Multi Barrier Reverse Convertible (50% European) on AXA SA, Commerzbank AG, UniCredit SpA
04.09.25 Goldminen: Wenn Disziplin das Metall schlägt
02.12.24 Jetzt ohne Trading-Gebühren regelmässig mit Vanguard ETFs sparen.
mehr

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’775.85 19.50 UUOSMU
Short 13’030.74 13.96 BFTSNU
Short 13’547.16 8.77 UK0BSU
SMI-Kurs: 12’318.39 09.09.2025 09:39:50
Long 11’749.31 19.04 SQBBAU
Long 11’493.58 13.65 BO0SVU
Long 11’023.53 9.00 BYCSSU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Meistgelesene Nachrichten

Diese Aktien empfehlen Experten zu verkaufen
BioNTech-Aktie im Fokus: Anleger schwanken zwischen Chancen und Risiken
Rüstungswerte im Rallymodus: Was den Aktien von Rheinmetall, RENK und HENSOLDT Rückenwind verleiht
Bitcoin-Crash 2026? Warum Experten vor Kursen unter 100'000 US-Dollar warnen
PepsiCo Aktie News: Anleger schicken PepsiCo am Nachmittag ins Minus
DroneShield-Aktie im Aufwind: Aufnahme in S&P/ASX 200 treibt Kurs an
NVIDIA-Chef Huang lobt TSMC und empfiehlt Kauf der Aktie
Berkshire Hathaway im Q2 2025: So investierte Warren Buffett - neue Aktien im Depot
Seres-Aktie haussiert - Nestlé-Titel tiefer: Nestlé hat Seres Therapeutics offenbar Übernahmeofferte vorgelegt
Rheinmetall Aktie News: Rheinmetall tendiert am Nachmittag nordwärts

Top-Rankings

KW 36: Das waren die Tops und Flops der SMI-Aktien in der vergangenen Woche
Der SMI stand in der vergangenen Woche einmal mehr im Bann von Konjunktur und Politik. So bewegt ...
Bildquelle: Maksim Kabakou / Shutterstock.com
KW 36: Das waren die Gewinner und Verlierer im DAX
Im Laufe der Woche kam es am deutschen Aktienmarkt zu Ausschlägen. So entwickelten sich die Einz ...
Bildquelle: Maksim Kabakou / Shutterstock.com
Die Performance der Kryptowährungen in KW 36: Das hat sich bei Bitcoin, Ether & Co. getan
Am Kryptomarkt bewegten sich einige Werte in der vergangenen Handelswoche stark. Das sind die Ge ...
Bildquelle: Wit Olszewski / Shutterstock.com
Alle Top-Rankings. Klicken Sie hier.

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}